← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #1889 OF 1,916 MOST-CITED

Written SOPs available for use by personnel

FDA cited this observation 5 times across 5 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Biologics5
BY FISCAL YEAR
FY20262
FY20221
FY20211
FY20171

How FDA worded it — real examples

Failure to make available written procedures for use by personnel in the areas where the procedures are performed.

New York Blood Center, Inc. · New York, New York · Biologics · 2026-07-17

Failure to make available written procedures for use by personnel in the areas where the procedures are performed.

New York Blood Center Enterprises · Rockville Centre, New York · Biologics · 2026-01-12

Failure to make available written procedures for use by personnel in the areas where the procedures are performed.

National Genetics Institute · Los Angeles, California · Biologics · 2022-03-02

Failure to make available written procedures for use by personnel in the areas where the procedures are performed.

New York Blood Center Enterprises · Massapequa, New York · Biologics · 2021-02-24

Failure to make available written procedures for use by personnel in the areas where the procedures are performed.

Vitalant · Chicago, Illinois · Biologics · 2016-11-08

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →